BACKGROUND AND PURPOSE: Recent studies have attributed the increased infection vulnerability of patients with stroke to stroke-induced immunosuppression. We have therefore explored the immunological changes in patients with ischemic stroke. METHODS: Blood from 46 patients with stroke was analyzed by fluorescent-activated cell sorter to determine leukocyte subsets. To identify changes that represent clinically relevant immunosuppression, we compared patients who developed infection within 14 days after stroke with those who did not. RESULTS: Stroke induced a dramatic and immediate loss of T-lymphocytes, most pronounced within 12 hours after stroke onset. Only patients with subsequent infection exhibited a delay in the recovery of CD4+ T-lymphocyte counts. CONCLUSIONS: Our data suggest that a loss of CD4+ T cell function contributes to the stroke-induced immunosuppression. The CD4+ T cell count on the day after stroke may emerge as a predictive marker for poststroke infection allowing, early identification of patients at risk.
BACKGROUND AND PURPOSE: Recent studies have attributed the increased infection vulnerability of patients with stroke to stroke-induced immunosuppression. We have therefore explored the immunological changes in patients with ischemic stroke. METHODS: Blood from 46 patients with stroke was analyzed by fluorescent-activated cell sorter to determine leukocyte subsets. To identify changes that represent clinically relevant immunosuppression, we compared patients who developed infection within 14 days after stroke with those who did not. RESULTS:Stroke induced a dramatic and immediate loss of T-lymphocytes, most pronounced within 12 hours after stroke onset. Only patients with subsequent infection exhibited a delay in the recovery of CD4+ T-lymphocyte counts. CONCLUSIONS: Our data suggest that a loss of CD4+ T cell function contributes to the stroke-induced immunosuppression. The CD4+ T cell count on the day after stroke may emerge as a predictive marker for poststroke infection allowing, early identification of patients at risk.
Authors: Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp Journal: Nat Rev Neurol Date: 2012-06-05 Impact factor: 42.937
Authors: Gabriel Courties; Fanny Herisson; Hendrik B Sager; Timo Heidt; Yuxiang Ye; Ying Wei; Yuan Sun; Nicolas Severe; Partha Dutta; Jennifer Scharff; David T Scadden; Ralph Weissleder; Filip K Swirski; Michael A Moskowitz; Matthias Nahrendorf Journal: Circ Res Date: 2014-10-31 Impact factor: 17.367
Authors: Frances Rena Bahjat; Rebecca L Williams-Karnesky; Steven G Kohama; G Alexander West; Kristian P Doyle; Maxwell D Spector; Theodore R Hobbs; Mary P Stenzel-Poore Journal: J Cereb Blood Flow Metab Date: 2011-02-02 Impact factor: 6.200
Authors: Wei-Na Jin; Andrew F Ducruet; Qiang Liu; Samuel Xiang-Yu Shi; Michael Waters; Ming Zou; Kevin N Sheth; Rayna Gonzales; Fu-Dong Shi Journal: FASEB J Date: 2018-01-08 Impact factor: 5.191
Authors: Grant C O'Connell; Madison B Treadway; Connie S Tennant; Noelle Lucke-Wold; Paul D Chantler; Taura L Barr Journal: Transl Stroke Res Date: 2018-03-17 Impact factor: 6.829
Authors: Andreas Hug; Bettina Mürle; Alexander Dalpke; Markus Zorn; Arthur Liesz; Roland Veltkamp Journal: Neurocrit Care Date: 2011-06 Impact factor: 3.210